Fresh Tracks Therapeutics Inc (NASDAQ:FRTX)
| 0.5999 Delayed Data As of 3:58pm ET |  +0.0086 / +1.45%Today’s Change | 0.45 Today|||52-Week Range 12.60 | -60.01% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $3.4M |
Company Description
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Contact Information
Fresh Tracks Therapeutics, Inc. 5777 Central Avenue Boulder Colorado 80301 |
Employees
Shareholders
| Other institutional | 2.95% |
| Mutual fund holders | 0.68% |
| Individual stakeholders | -- |
Top Executives
| Andrew D. Sklawer | President & Chief Executive Officer |
| Deepak Chadha | Chief Operating, Research & Development Officer |
| Albert N. Marchio | Chief Financial Officer |
| Nancy Seretta | Head-Clinical Operations |
| David R. McAvoy | Chief Compliance Officer & General Counsel |
